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Background: GOLPH2 (Golgi phosphoprotein 2) is a novel Golgi membrane protein. Despite its unknown
physiologic function, however, it has been proposed as a biomarker for hepatocellular and prostate carcinoma due
to its upregulation in those cancer entities. Whether the overexpression of GOLPH2 is tumour specific or a generic
parameter of malignancy and whether this finding is true for additional carcinomas has not been determined. In
this study, we aimed to evaluate the expression pattern of GOLPH2 in testicular seminomas, the most common
histologic subtype of testicular neoplasm.
Methods: GOLPH2 protein expression was assessed by immunohistochemistry in 69 testicular seminomas and
compared to the expression rates in matching normal testicular tissue and intratubular germ cell neoplasia of
unclassified type (IGCNU). In addition, a subset of Leydig cell tumours was analyzed accordingly.
Results: GOLPH2 was consistently overexpressed (89.9%) in seminomas. Matching non-neoplastic tissue showed
weak or negative staining. The observed differences between non-neoplastic and neoplastic tissue were statistically
highly significant (p < 0.001). There were no significant associations with tumour status. Interestingly, GOLPH2 was
also highly expressed in the intertubular Leydig cells as well as in Leydig cell tumours.
Conclusions: GOLPH2 protein is highly expressed in seminomas and in Leydig cell tumours. This study fosters the
association of GOLPH2 with malignant neoplastic processes. The staining pattern is easily assessable and consistent
which is a favourable property especially in clinical settings. GOLPH2 could be a novel immunohistochemical
marker for the assessment of testicular neoplasms, especially against the background that in analogy to
hepatocellular carcinomas complementary GOLPH2 serum levels might be helpful in detecting metastases or
recurrent tumour. Therefore serum studies and analyses of GOLPH2 expression in non-seminomatous germ cell
tumours are strongly warranted.
Background
Testicular neoplasms represent the most common
malignancy in young adults with rising incidence [1,2].
The two major categories are testicular germ cell
tumours (GCT) and sex cord-stromal tumours. GCT is
a highly heterogeneous group of neoplasms divided into
seminomas and non-seminomas. The most frequent sin-
gle histologic subtype of GCT is seminoma which con-
sists of uniform tumour cells resembling gonocytes that
are unable to undergo normal spermatogenesis owing to
a blocked regular differentiation [3]. Among non-germ
cell tumours, Leydig cell tumours (LCT) are the most
common entity. Despite the generally benign behaviour
of the majority of LCT, 10% are malignant and charac-
terized by limited response to chemotherapy and
irradiation and poor prognosis. In comparison to other
G C T ,s e m i n o m a sh a v eam o r ef a v o u r a b l ep r o g n o s i s
even in advanced stages. Surgery and systemic treatment
regimens in combination with radio- and chemotherapy
are able to cure this malignancy in the majority of cases.
Consequently, rising numbers of long term survivors
have turned the focus more and more to the long term
effects of chemotherapeutic treatments. Delayed toxicity
and the development of secondary malignancies are a
problem of many of today’s anti-neoplastic armamentar-
ium. Unfortunately, the young age of the typical semi-
noma patient further enhances the time at risk for the
side effects of these therapies. Despite the progress in
treatment GCT still remain to be a deadly disease for a
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resistance. Therefore, the demand remains to further
characterize this tumour entity to better understand and
predict the biological behaviour and to identify targets
for more sophisticated and risk-adapted therapeutic
options. The novel Golgi phosphoprotein 2 (GOLPH2),
also known as Golgi protein 73 (GP73) and Golgi mem-
brane protein 1 (GOLM1), has recently been described
as a diagnostic marker in prostate cancer with similar
characteristics as alpha-methylacyl CoA racemase [4].
Likewise, GOLPH2 mRNA could be used in a combina-
tion of markers to detect prostate cancer from urine
samples [5]. Furthermore, in liver diseases several stu-
dies demonstrated the utility of GOLPH2 as a serum
marker of hepatocellular carcinoma [6-10]. Since only a
few studies on GOLPH2 exist until present, it is
unknown whether the described upregulation and
detectability in tumour tissue and various body fluids is
specific for certain types of cancer. GOLPH2 could also
either be generally involved in carcinogenesis similar to
p53 or, more likely, given the lack of information on
mutations of GOLPH2 in cancer, could be secondarily
upregulated in carcinomas without any causative rela-
tions to carcinogenesis.
GOLPH2 protein is coded by the GOLM1 gene on
chromosome 9q21.33 and was first described in giant-
cell hepatitis [8]. Structurally, GOLPH2 protein consists
of a short cytoplasmic N-terminal domain, a membrane-
spanning region, some coiled-coil domains and a longer
luminal C-terminal domain. Several possible glycosyla-
tion sites are integrated in the protein structure, but
their role is still undetermined. Apart from its associa-
tion with the Golgi apparatus, the functional properties
of GOLPH2 are still elusive. The Golgi apparatus is a
structurally highly complex central processing station
which ensures proper glycosylation of secretory proteins
before transported to their final destination. The critical
physiologic importance of the function of the Golgi
apparatus is reflected in the broad spectrum of disorders
like the family of congenital disorders of glycosylation
and muscular dystrophies. Modification in glycosylation
has been linked to cancer metastasis. Due to the diverse
and heterogeneous function of proteins trafficking
through the Golgi system the location of GOLPH2
within the Golgi membrane suggests possible roles in
intracellular transportation, cell signalling, protein con-
struction and modification or structural or maintenance
tasks. A recent study using a mouse model with c-term-
inally truncated GOLPH2 lead to decreased survival
especially in females and severely impaired renal and
liver epithelial organization and underscores the func-
tional importance of GOLPH2 [11]. In this study, we
analyzed the expression pattern of the novel cancer




Sixty-nine patients diagnosed with testicular seminoma at
the Institute of Pathology, Charité - Universitätsmedizin
Berlin between 1997 and 2007 were enrolled in this
study. All tumours were pure seminomas without any
other germ cell tumour component. Cases were selected
according to tissue availability and were not stratified for
any known preoperative or pathological prognostic factor.
Histological diagnosis was established according to the
guidelines of the World Health Organization. The study
has been approved by the Charité University Ethics Com-
mittee under the title “Retrospective analysis of tissue
samples by immunohistochemistry and molecular biologi-
cal methods” (EA1/06/2004) on 20
th September 2004.
Patient age ranged between 25 and 70 years with a
median of 37. The pT status was as follows: pT1 - 50
(72.5%), pT2 - 16 (23.2%) and pT3 - 3 (4.3%). Matching
normal tissue was present for 55 cases.
Tissue Micro Array construction
A tissue-micro-array (TMA) was constructed from for-
malin-fixed paraffin embedded tissue as previously
described [12]. We used a tissue arrayer from Beecher
Instruments (Woodland, CA, USA). The punch diameter
was 1.5 mm. Each case was represented by two tumour
cores and according to tissue availability by two tissue
cores from non-tumourous testicular parenchyma. In 12
cases intratubular germ cell neoplasia of unclassified
type (IGCNU) was available.
Immunohistochemistry
The TMA blocks were freshly cut (3 μm) and mounted
on superfrost slides (Menzel Gläser, Braunschweig, Ger-
many). Immunohistochemistry was conducted with the
Ventana Benchmark automated staining system (Ven-
tana Medical Systems, Tucson, AZ) using Ventana
reagents for the entire procedure. To detect GOLPH2, a
commercially available antibody (mouse monoclonal,
clone 5B10, Abnova Corporation, Taipei, Taiwan, cata-
log number H00051280-M06, dilution 1:500) was
diluted in a Ventana diluent. For primary antibody
detection we used the UltraVIEW™ DAB detection kit
using the benchmarks CC1m heat induced epitope
retrieval. Slides were counterstained with hematoxylin,
dehydrated and mounted.
Evaluation of the immunohistochemical stainings
The immunostainings were evaluated by two genitour-
inary pathologists blinded for patient outcome on a
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evaluated with a four-tiered grading system (0 = nega-
tive, 1 = weak, 2 = moderate and 3 = strong staining
intensity). We used a 10% threshold to determine posi-
tivity. To delineate between low and high levels of
GOLPH2 expression we used the median staining
intensity as cut-off point.
Statistical analysis
Statistical analysis was performed using SPSS (version
16.0; SPSS Inc., Chicago, IL, USA). The statistical sig-
nificance of the associations between GOLPH2 expres-
sion and clinico-pathological parameters were assessed
with Fisher’se x a c tt e s ta n dc
2-tests. The Wilcoxon
rank-sum test was used to determine intergroup differ-
ences. P values <0.05 were considered statistically
significant.
Results
Typically GOLPH2 expression was located in the peri-
nuclear cytoplasm, being in line with the location of the
Golgi apparatus. The staining pattern was fine granular
with occasional cluster formation in the seminomas
(Figure 1). For 55 cases normal tissue was available. The
majority of germ cells in non-neoplastic tubules were
either negative or displayed a patchy slightly positive
GOLPH2 staining. Most interestingly, intertubular Ley-
dig cell clusters showed a pronounced granular
GOLPH2 expression which clearly demarcated these
cells from other interstitial cells and from the intratubu-
lar cells. This positivity for GOLPH2 in the Leydig cells
initiated a subsequently performed immunohistological
analysis of four archival Leydig cell tumours. These
stainings revealed a consistent GOLPH2 expression in
all four cases (Figure 2).
Figure 1 GOLPH2 immunohistochemistry in testicular parenchyma and seminoma. In normal testicular tubules GOLPH2 is rather absent
(A) or faintly expressed (B) in the germ cell lining of the tubules. Meanwhile the intertubular Leydig cells display a pronounced perinuclear
GOLPH2 staining. In seminomas we observed weak (C), moderate (D/E) and strong (F) granular and perinuclear GOLPH2 stainings. The majority
of the seminomas displayed the moderate intensity (D/E) expression pattern.
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moderate and 8 (11.6%) a strong GOLPH2 expression.
The typical staining pattern, as described above, was
consistent with that previously described in other
tumours and was clearly detectable in most of the cells
of the respective seminoma. Only 7 (10.1%) cases had a
weak GOLPH2 staining resembling that of the normal
tubular germ cells.
The observed differences between non-neoplastic and
neoplastic tissue were statistically highly significant
(p < 0.001). The staining of the intratubular germ cell
neoplasia of unclassified type was negative (3 cases) or
weak (9 cases). The GOLPH2 ex p r e s s i o ni ns e m i n o m a s
was not associated with tumour status or patient age
(Table 1).
Discussion
This study demonstrates for the first time that
GOLPH2 is a significantly overexpressed protein in
seminomas in comparison to normal testicular
parenchyma. Wright et al. previously described the
location of GOLPH2 in germ cells and Sertoli cells in
mouse [11]. Using the c-terminally truncated form of
GOLPH2 the authors did not detect histologic mor-
phology changes in the testis and concluded that no
impairment of testicular development was involved.
The overexpression in seminomas as opposed to nor-
mal germ cells reported here suggests that GOLPH2 is
linked to testicular carcinogenesis. More precisely, the
expression level increased from precursor lesion in
IGCNU to seminomas. Our findings in testicular neo-
plasms mirror the previous results of our group and
others in prostate cancer and hepatocellular carcinoma
[4,13-15].
In addition, GOLPH2 is distinctively expressed in Ley-
dig cells. No published data was available to date report-
ing on this prominent feature. Taken into consideration
that GOLPH2 expression in normal tissues of multiple
organs was widely found to be minimal or absent [11],
this interesting finding raised the question whether the
overexpression could also be detected in LCT which
could be confirmed by our subsequent analysis. Current
diagnosis of malignant Leydig cell tumours harbouring
metastatic potential is mainly based on morphologic
characteristics of tumours cells due to lack of appropri-
ate biomarkers. Immunohistochemical markers such as
Calretinin, alpha-Inhibin, S100 protein and Melan-A
were shown be of some value but still lack sufficient
specificity [16]. Notably, when evaluating patients with
metastasis to the testis the differentiation from adreno-
cortical cells and melanoma cells may be problematic
due to the overlapping positivity for the latter two mar-
kers [17]. Further expression analyses of GOLPH2 are
warranted in particular in conjunction with clinical fol-
low-up data to evaluate the prognostic utility of
GOLPH2 as a biomarker in LCT. Given the rarity of
LCT, however, studies including a larger number of
cases can be challenging. Our findings indicate that
GOLPH2 can be applied as a marker to identify Leydig
cells and Leydig cell tumours. For differential diagnostic
Figure 2 GOLPH2 immunohistochemistry in Leydig cell
tumours. GOLPH2 expression in two exemplary Leydig cell tumours
(A/B).
Table 1 Associations (c
2-tests) between the protein
expression GOLPH2 in seminomas and clinico-
pathological parameters
Total GOLPH2 low GOLPH2 high p-value
All cases 69 (100%) 7 (10.1%) 62 (89.9%)
Age 0.632
≤36 29 (42%) 3 (10.3%) 26 (89.7%)
>36 40 (58%) 4 (10%) 36 (90%)
pT-status 0.868
pT1 50 (72.5%) 6 (12.0%) 44 (88.0%)
pT2 16 (23.2%) 0 (0) 16 (100%)
pT3 3 (4.3%) 1 (33.3%) 2 (66.7%)
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tumours further investigations are needed.
It seems likely that GOLPH2 upregulation is a charac-
teristic finding of malignant tissues not only restricted
to the few cancer types that were previously described.
Our research group was able to confirm the expression
of GOLPH2 in hepatocellular carcinoma [14], but we
also detected GOLPH2 in various other malignancies on
a multi-tissue-micro-array which argues against a
hepato- or prostate-specificity of this biomarker [18].
Interestingly, there is a circulating form of GOLPH2
found in hepatocellular carcinoma [6]. Serum levels of
GOLPH2 were higher in cancer patients when com-
pared to healthy individuals, which lead to the proposal
of GOLPH2 as a novel serum marker in this entity
[10,19]. Here, we did not include an analysis of blood
samples. Studies addressing the question whether
GOLPH2 serum levels of seminoma patients differ from
those of healthy individuals and whether serum
GOLPH2 could be used as a clinical marker to detect
early disease relapse may be of particular clinical
interest.
We did not find associations with tumour status or
patient age. Considered that the expression pattern was
consistently high among all samples, this was not surpris-
ing. Comparably, no prognostically relevant associations
between GOLPH2 and the above mentioned parameters
was found in our previous studies on prostate cancer,
hepatocellular carcinoma or renal cell cancer [4,14,18].
The marked GOLPH2 expression in normal Leydig cells
and Leydig cell tumours suggest that GOLPH2 may have
more specific physiologic functions in those cells.
GOLPH2 upregulation in a liverc e l ll i n eb ya d e n o v i r u s
infection further supports the view that apart from neo-
plastic processes other causes exist for the upregulation
and expression of GOLPH2 such as inflammation and
increased endocrine function [9,20]. Leydig cells are endo-
crine active cells secreting a variety of hormones including
androgens and estrogens. In the prostate, GOLPH2 is also
strongly upregulated in benign hyperplastic glands of the
transitional zone. Both androgenic and estrogenic stimula-
tion are causally related to prostatic hyperplasia [21]. In
fact, normal function of Leydig cells in the testes are
essential for the development of this condition as hyper-
plasia doesn’t occur in men castrated before onset of pub-
erty. Auxillary studies will provide more insight to the
functional properties of GOLPH2 in endocrine tissue,
inflammatory processes and malignant tumours.
Conclusion
GOLPH2 protein is significantly upregulated in semino-
mas of the testis in comparison with non-neoplastic testi-
cular germ cells. The staining pattern is easily assessable
and consistent which is a highly favourable property
especially in clinical settings. No associations with clinico-
pathological characteristics were observed. Although the
overexpression in seminomas and Leydig cell tumours fos-
ter the association of GOLPH2 with malignant neoplastic
processes, the high expression rates in normal Leydig cells
may suggest a more differentiated picture and underlines
the need for functional analyses of GOLPH2 in the differ-
ent physiologic and pathologic circumstances. GOLPH2
might be a novel immunohistochemical marker for semi-
nomas, but to clarify its differential diagnostic value addi-
tional studies are warranted.
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